FIELD: pharmaceutical chemistry.
SUBSTANCE: group of inventions relates to pharmaceutical chemistry and includes a compound of the formula (II), specific macrocyclic compounds specified in the claims, their stereoisomers and pharmaceutically acceptable salts, as well as their use in the manufacture of a drug. In the formula (II), R1 is selected from H and C1-3alkyl; R5 is selected from H and C1-3alkyl, where C1-3alkyl is optionally substituted with R, R6 is such as specified in the claims; r and m are equal to 1 or 2; D is selected from -N(R2)- and -C(R3)(R4)-; R2 is selected from H and C1-3alkyl; R3 and R4 are independently selected from H, F, Cl, Br, I, NH2, and C1-3alkyl, where NH2 is optionally substituted with R, while R is equal to 1,2, or 3; alternatively, R3 and R4, together with a carbon atom, to which they are attached, form 5-6-element heterocycloalkyl, which contains N as a heteroatom, a number of heteroatoms is equal to one or two, where 5-6-element heterocycloalkyl is optionally substituted with R, while R is equal to 1,2, or 3; R6 is selected from H, F, Cl, Br, I, C1-3alkoxy, and -O-C3-6cycloalkyl, where C1-3alkoxy is optionally substituted with R, while R is equal to 1, 2, or 3; R7 is selected from H, F, Cl, Br, I, C1-3alkyl, C1-3alkoxy, and 5-6-element heterocycloalkyl, which contains N as a heteroatom, a number of heteroatoms is equal to one or two, where C1-3alkyl, C1-3alkoxy, and 5-6-element heterocycloalkyl are optionally substituted with R, while R is equal to 1, 2, or 3; alternatively, R6 and R7, together with ring atoms, to which they are attached, form a ring A, while the ring A is 5-6-element heterocycloalkyl, which contains N as a heteroatom, a number of heteroatoms is equal to one or two, which optionally substituted with R, and R is equal to 1, 2, or 3; R is independently selected from OH, C1-3alkyl, C1-3alkoxy, and C1-3dialkylamino.
EFFECT: macrocyclic compounds showing inhibitory activity relatively to Wee1 kinase.
20 cl, 8 tbl, 42 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVE BASED ON DIHYDROPYRIMIDO-RING AS HBV INHIBITOR | 2015 |
|
RU2693897C2 |
| PDE4 INHIBITOR | 2017 |
|
RU2743126C2 |
| PYRIMIDOIMIDAZOLE COMPOUNDS USED AS DNA-RK INHIBITORS | 2020 |
|
RU2796163C1 |
| LSD1 INHIBITOR, AS WELL AS ITS PRODUCTION METHOD AND ITS APPLICATION | 2018 |
|
RU2763898C2 |
| PYRIDOPYRIMIDINE COMPOUNDS ACTING AS DOUBLE INHIBITORS OF mTORC 1/2 | 2018 |
|
RU2771201C2 |
| COMPOUNDS BASED ON 7-SUBSTITUTED PYRROLOTRIAZINE OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND METHODS FOR THEIR PREPARATION AND APPLICATION | 2018 |
|
RU2745548C1 |
| TRICYCLIC COMPOUNDS AFFECTING CRBN PROTEINS | 2019 |
|
RU2801068C2 |
| FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
| S1P1 AGONIST AND ITS APPLICATION | 2017 |
|
RU2754845C2 |
| THIENODIAZEPINE DERIVATIVES AND THEIR USE | 2018 |
|
RU2795005C2 |
